Catalyst Wire Dossier Catalyst Wire Dossier

Sumatriptan intranasal powder

sumatriptan · Avanir Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sumatriptan intranasal powder, covering 2017-03-14 to 2017-03-14. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura [Phase 3]

See pricing